Pear Therapeutics Launches Pear Prescription Digital Therapeutics Digest, Provides Roadmap for Payer Coverage Considerations
Pear Therapeutics, in collaboration with Avalere Health, conducted a survey of payers and employers to develop and publish the first annual Pear Prescription Digital Therapeutics Digest (Pear PDT Digest), outlining current challenges and opportunities with PDTs, identifying barriers to coverage, and proposing solutions and recommendations to inform coverage decisions, and ultimately improving patient access.
This project supports efforts from key industry leaders such as the Academy of Managed Care Pharmacy (AMCP) and the Digital Therapeutics Alliance (DTx Alliance) to define the coverage landscape and provide guidance to payers. AMCP has recently identified the following as key considerations3 to improve support for appropriate and evidence-based coverage decisions for digital therapeutics, including the:
The Pear PDT Digest incorporates findings from a survey of 40 major US payers and employers on their perspectives of the PDT market landscape. All respondents reported a high level of familiarity with PDTs as a requirement for participating in the survey. Variation in stakeholder responses regarding coverage and reimbursement pathways for PDTs confirms fundamental misconceptions about PDTs among key players in this space.
The survey results address the following key questions, as they relate to market access for PDTs, including:
This Digest is the first in a series of publications in which we will provide key insights, as they relate to PDTs, and track payers’ level of familiarity with—and management of—PDTs. The goal of this Digest series is to provide a road map for payers and employer groups to use as a starting point as they review, cover, and manage PDTs.
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.